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a mouse model of
JMML (Shp2E76K) and
regulates the number of
leukemic cells.
• Low expression of
Morrbid/MORRBID is
associated with im-
proved survival in mice
and humans.
Mutations in PTPN11, which encodes the protein tyrosine phosphatase SHP2, contribute
to ;35% of cases of juvenile myelomonocytic leukemia (JMML). A common clinical picture
in children with JMML is that it presents as a constitutive hyperinflammatory syndrome,
partially reminiscent of chronic myelomonocytic leukemia in adults. Thus, a component of
JMML is associated with a hyperinflammatory state and abundant innate immune cells such
as neutrophils and monocytes. Recently, we showed that the evolutionarily conserved
mouse lncRNAMorrbid is specifically expressed in myeloid cells and uniquely represses the
expression of the proapoptotic gene Bim to regulate the lifespan of myeloid cells. However,
its role in JMML has not been investigated. In this study, we characterized the role of
Morrbid and its target Bim, which are significantly dysregulated in Shp2E76K/1-bearing
myeloid cells, in driving JMML. Loss of Morrbid in a mouse model of JMML driven by the
Shp2E76K/1 mutation resulted in a significant correction of myeloid and erythroid cell
abnormalities associated with JMML, including overall survival. Consistently, patients with
JMML who had PTPN11, KRAS, and NRAS mutations and high expression of MORRBID
manifested poor overall survival. Our results suggest that Morrbid contributes to JMML
pathogenesis.
Introduction
Juvenile myelomonocytic leukemia (JMML) is the most common myeloproliferative neoplasm (MPN) in
childhood. JMML is characterized by mutations in NF1, CBL, KRAS, NRAS, or PTPN11, and cells from
JMML patients show hypersensitivity to GM-CSF in vitro.1-3 Traditional cytotoxic chemotherapeutic
agents are ineffective in JMML, and the only curative modality is allogeneic hematopoietic stem cell
transplantation.4 As the most prevalent mutation in children with MPN, the activated gain-of-function
mutation in PTPN11, which encodes the protein tyrosine phosphatase SHP2, contributes to ;35% of
cases of JMML, and leads to hyperactive Ras-MAPK signaling.5
A common clinical picture in JMML is that it presents as a hyperinflammatory syndrome and is often
indistinguishable from viral infections.6 Unlike acute myeloid leukemia (AML) but similar to CMMLchronic
myelomonocytic leukemia, JMML rarely progresses to a blast crisis; rather, death is caused by
extramedullary myeloid cell expansion and enhanced survival, leading to organ failure, respiratory failure,
bleeding, and infection.1 SHP2 mutations such as SHP2E76K/1 and SHP2D61Y/1 downregulate the
expression of the proapoptotic protein Bim, which is associated with enhanced survival relative to
controls.7 Loss of Bim in hematopoietic progenitor cells enhances their survival and shows resistance to
apoptosis.8,9
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Despite the discovery of transcripts derived from the noncoding
genome, how these noncoding RNAs, including long noncoding
RNAs (lncRNAs), regulate MPN initiation or development is poorly
understood. Although only a few lncRNAs related to myeloid
malignancies have been described, their function and the targets
that they regulate is largely unknown.10 We have recently shown
that, under physiologic conditions, the evolutionarily conserved
novel lncRNA Morrbid is uniquely expressed in myeloid cells and
represses the expression of the proapoptotic gene Bim to regulate
the lifespan of these cells.11 Using murine Shp2E76K-driven JMML
models and a JMML patient database, we studied the role of
MORRBID in disease initiation and progression. Although genetic
loss of Morrbid partially mitigates signatures of JMML, our results
show that Morrbid plays a role in the onset and progression of the
disease.
Methods
All the animal experiments were approved by the Laboratory Animal
Resource Center at Indiana University School of Medicine. All
strains were on a C57/B6 background, and wild-type (WT) mice
were procured from the Indiana University School of Medicine Core
Facility. JMML model mice (LysMCre; Ptpn11E76K/1) and Morrbid-
deficient mice (Morrbid2/2) have been described11,12 and were
bred to generate the compound mutants. Analysis involving mouse













































































































































































































Figure 1. Loss of Morrbid enhances the survival of Shp2E76K-driven JMML mice. (A) Generation of JMML mice (Shp2*: LysMCre; Shp2E76K/1) and JMML mice lacking
Morrbid (Shp2*M: LysMCre; Shp2E76K/1; Morrbid2/2) along with WT control and Morrbid2/2 (M). (B) Kaplan-Meier survival curve of Shp2* and Shp2*M mice and control
animals. (C) Analysis of hematopoietic cells in PB by the automatic blood cell counter Element HT5 Analyzer. (D) Analysis of WBCs from PB by flow cytometry. Mac11
staining for myeloid cells and CD191 staining for B cells (n 5 4-18 mice). *P , .05; **P , .01; ***P , .001; ****P , .0001. See supplemental Figure 1 for improvement of
the anemia phenotype in Shp2*M mice compared with Shp2* mice. LY, lymphocytes; n.s., not significant.
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for annexin-V and anti-Bim) have been described.13 Unless stated
otherwise, statistical analysis in animal experiments was performed
with GraphPad Prism 6 for Kaplan-Meier survival curve compar-
ison or using Student t test or 1-way analysis of variance for group
comparison.
The bioinformatics analysis of MORRBID in human JMML was
conducted as follows. To identify which lncRNAs potentially
associate with JMML, we downloaded raw microarray data for
JMML samples, with or without PTPN11, KRAS, and NRAS
mutation from the GEO database (GSE71935),14 along with the
pertinent clinical data on the patients. The downloaded data
were normalized by the MAS5 method. Survival analysis was
performed over the expression of lncRNAMORRBID and clinical
data, using the log-rank test encoded in the survival R package
(https://github.com/therneau/survival). Considering that the data of
very young patients (,18 months) were not representative of the
disease progression, only older patients with JMML (.18 months at
the last follow-up) were included for survival analysis in the study.
Results and discussion
Shp2 is indispensable for hematopoiesis.15,16 Hematopoietic cells
expressing the gain-of-function isoform of Shp2, Shp2E76K, which
mimics the human PTPN11 mutation in JMML, confer cell survival
advantage and alterations in cell proliferation and differentiation.12
The murine model bearing Shp2E76K (Ptpn11E76K/1) driven by
lysosome-cre (LysMCre; Ptpn11E76K/1, indicated as Shp2* mice
hereafter) is often used to study JMML, because it induces acute
alterations in hematopoiesis similar to human JMML.12,15 We have
shown that, in inflammatory conditions, the expression of lncRNA
Morrbid is elevated, whereas the level of Bim is downregulated.11
Consistently, we have shown that Morrbid is upregulated, and Bim
is downregulated in myeloid cells derived from Shp2* mice.13 To
test the functional requirement of Morrbid in the development of
JMML, we generated a mouse model of JMML that lacked Morrbid:
LysMCre; Shp2E76K/1; Morrbid2/2 (indicated herein as Shp2*M).
We compared the disease progression betweenShp2* and Shp2*M
mice, along with WT and Morrbid2/2 (M) controls (Figure 1A).
We assessed overall survival of Shp2*M mice relative to Shp2*
controls up to a year (Figure 1A). Although both WT and M mice
showed a normal lifespan, the median survival for Shp2* mice was
170 days, which was extended to 270 days for Shp2*M mice (n 5
4-10; *P 5 .01), indicating that Shp2*M mice show an improved
overall lifespan (Figure 1B). We next compared the hematological
parameters in peripheral blood (PB), bone marrow (BM), and spleen
of 4 experimental groups. At the moribund or semimoribund stage
(typically, 5-6 months for Shp2* and 8-9 months for Shp2*M), both
Shp2* and Shp2*M mice showed comparable high overall white
blood cell (WBC) counts and neutrophil (NE) and monocyte (MO)
counts in PB (;10-fold higher than WT; data not shown). At 1 to
4 months of age, compared with WT mice, Shp2* mice developed
JMML-like symptoms, including higher WBC, NE, and MO counts,
which were noted in animals as young as 3 to 4 weeks. At the same
age, however, Shp2*M mice showed significantly lower WBC, NE,
and MO counts compared with Shp2* mice (Figure 1C). Further-
more, the percentage of NEs and MOs in WBCs was also reduced
in Shp2*M mice compared with that in Shp2* mice, but was still
higher than that in WT (Figure 1C). Consistent with these findings,
flow cytometry showed a significant correction in the frequency
of Mac-11 cells in Shp2*M mice compared with Shp2* mice
(Figure 1D).
To determine whether the loss of Morrbid alters the hematopoietic
abnormalities associated with Shp2*mice in the BM and spleen, we
again analyzed all 4 groups of mice at 3 to 4 months of age. A
significant difference in the frequency of granulocyte-macrophage
progenitors (GMPs) was observed in the BM of WT and Shp2*
mice (Shp2* vs WT, P , .01; Figure 2A). In contrast, although the
increased frequency of GMPs was not modulated in Shp2*M mice,
the BM cellularity in Shp2*M mice was significantly reduced
compared with that in Shp2* mice (Shp2* vs Shp2*M, P , .05;
Figure 2C). Thus, the absolute number of GMPs in Shp2*M mice
was significantly reduced compared with the number in Shp2*mice
(Shp2* vs Shp2*M, P , .01; Figure 2C). With regard to mature
myeloid cells in the BM, both the frequency and the absolute
number of Mac11 cells were significantly reduced in Shp2*M mice
compared with Shp2*mice (Figure 2B-C). Consistent with previous
reports, Shp2* mice manifested an obvious splenomegaly com-
pared with WT mice as young as 1 month. Although, spleen weight
and size were comparable between Shp2* and Shp2*M mice at all
time points examined (data not shown), Shp2*M mice showed
a correction in the frequency of both GMPs and Mac11 cells
compared with Shp2* mice (Figure 2D-E). Furthermore, although
Shp2*M mice rapidly developed anemia at the moribund stage,
similar to Shp2* mice, the onset of the anemia was much later and
milder in young Shp2*M mice than in Shp2* mice. At 2 to 4 months
of age, Shp2*M mice showed normal frequency of erythroid
progenitors, red blood cell counts, and hemoglobin concentration,
similar to WT mice, whereas Shp2* mice showed impaired
maturation of erythroid progenitors (supplemental Figure 1).
Given the correction in the frequency and absolute number of
Mac-11 cells in Shp2*M mice compared with Shp2* mice, we
Figure 2. Loss of Morrbid rescues mature and immature myeloid cells in the BM and spleen of Shp2* mice. Mononuclear cells were collected from the BM (A-C)
and spleens (D-E) of the 4 experimental groups (WT, Shp2*, M, and Shp2*M; age, 3-4 months) for analyzing hematopoiesis. Changes in myeloid progenitors, GMPs, and
mature myeloid cells were analyzed. Lin2Sca12cKit1 cells were pregated for GMP flow cytometry profiles (CD341CD161). In BM, both the frequency and number of GMPs
and mature myeloid cells were quantified. In spleen, only the frequency of GMPs and mature myeloid cells was quantified. (F) The level of apoptosis in mature myeloid cells
was determined by flow cytometry using annexin-V staining, a marker for proapoptosis. (G) The level of Bim expression in mature myeloid cells was determined by intracellular
flow cytometry with an anti-Bim antibody. (H) Kaplan-Meier survival plots of JMML patients with high or low expression of MORRBID. The purple line indicates the survival curve
of children with JMML who had high expression of MORRBID (n 5 10 patient samples: 8 with mutations in PTPN11, 1 in KRAS, and 1 in NRAS; age .18 months), and the
green line indicates that of JMML children with low expression of MORRBID (n 5 7 patient samples; 3 with mutations in PTPN11 and 4 in NRAS; age .18 months). The high
expression of MORRBID was associated with poor overall survival of these patients (P 5 0.049). See supplemental Figure 2 for the survival curve of JMML patients without
mutations in PTPN11, KRAS, and NRAS. (I) Model for Morrbid regulation of myeloid cell survival in JMML. For mouse samples, n 5 4 mice; for human samples, n 5 7-10.
*P , .05; **P , .01; ***P , .001; ****P , .0001.
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sought to determine the extent to which loss of Morrbid in these
cells impacts their survival. Reduced apoptosis observed in Mac-11
Shp2* cells was normalized to WT levels in Shp2*M Mac-11 cells
(Figure 2F-G), which was associated with increased expression of
Bim compared with controls (Figure 2G). These results show that
targeting Morrbid in Shp2* Mac-11 cells induces apoptosis and
significantly corrects the absolute number of mature myeloid cells in
the BM, spleen, and PB (Figure 2I).
To assess whether MORRBID also plays a role in human JMML,
we conducted data mining studies to assess the correlation
between expression ofMORRBID and JMML prognosis. In a limited
number of human JMML samples with PTPN11, KRAS, and NRAS
mutations, we found that children with JMML who showed increased
expression of MORRBID were associated with poor overall survival
compared with patients who had low levels ofMORRBID (Figure 2H;
n 5 7-10; P 5 .049; patients aged .18 months were included
for survival analysis, whereas those aged ,18 months were
excluded). These data are consistent with our survival studies
using the murine model of JMML shown in Figure 1B. Moreover,
although it was not statistically significant because of the small
sample size, we observed a similar trend between MORRBID
expression and survival in patients with JMML lacking mutations in
PTPN11, KRAS, and NRAS (n 5 9 for each subgroup; P 5 .227;
supplemental Figure 2).
In summary, our results demonstrate an essential role forMorrbid
in regulating the pathogenesis of Shp2E76K mice, including
hematologic abnormalities and mortality seen in this model of
human JMML. Future studies will determine how inhibition of
MORRBID in JMML patient-derived cells affects their growth and
engraftment in mice. In addition, it would also be prudent to
assess the impact of Morrbid deletion in a model of Shp2E76K in
which Shp2E76K is active in hematopoietic stem cells. Although
Morrbid is expressed in myeloid cells, use of a conditional
knockout model of Morrbid to assess its function specifically in
hematopoietic stem cells would shed new light on how Morrbid
contributes to the JMML phenotypes driven by Shp2E76K in
stem cells.
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